GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (STU:4OR1) » Definitions » Cyclically Adjusted PB Ratio

Organovo Holdings (STU:4OR1) Cyclically Adjusted PB Ratio : 0.11 (As of Jun. 09, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Organovo Holdings Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Organovo Holdings's current share price is €0.855. Organovo Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €8.13. Organovo Holdings's Cyclically Adjusted PB Ratio for today is 0.11.

The historical rank and industry rank for Organovo Holdings's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:4OR1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.1   Med: 0.35   Max: 3.07
Current: 0.11

During the past years, Organovo Holdings's highest Cyclically Adjusted PB Ratio was 3.07. The lowest was 0.10. And the median was 0.35.

STU:4OR1's Cyclically Adjusted PB Ratio is ranked better than
86.23% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs STU:4OR1: 0.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Organovo Holdings's adjusted book value per share data for the three months ended in Mar. 2024 was €0.329. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.13 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Organovo Holdings Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Organovo Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings Cyclically Adjusted PB Ratio Chart

Organovo Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.27 1.49 0.47 0.22 0.11

Organovo Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.17 0.13 0.12 0.11

Competitive Comparison of Organovo Holdings's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Organovo Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organovo Holdings's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's Cyclically Adjusted PB Ratio falls into.



Organovo Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Organovo Holdings's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.855/8.13
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organovo Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Organovo Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.329/131.7762*131.7762
=0.329

Current CPI (Mar. 2024) = 131.7762.

Organovo Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201406 8.239 100.560 10.797
201409 10.313 100.428 13.532
201412 9.739 99.070 12.954
201503 11.037 99.621 14.599
201506 16.450 100.684 21.530
201509 14.698 100.392 19.293
201512 13.716 99.792 18.112
201603 12.087 100.470 15.853
201606 10.566 101.688 13.692
201609 9.977 101.861 12.907
201612 12.914 101.863 16.706
201703 11.154 102.862 14.289
201706 9.642 103.349 12.294
201709 8.171 104.136 10.340
201712 7.513 104.011 9.519
201803 6.513 105.290 8.151
201806 6.248 106.317 7.744
201809 5.783 106.507 7.155
201812 5.325 105.998 6.620
201903 5.181 107.251 6.366
201906 4.910 108.070 5.987
201909 4.326 108.329 5.262
201912 3.994 108.420 4.854
202003 3.692 108.902 4.468
202006 3.370 108.767 4.083
202009 2.521 109.815 3.025
202012 2.397 109.897 2.874
202103 3.797 111.754 4.477
202106 3.562 114.631 4.095
202109 3.353 115.734 3.818
202112 3.181 117.630 3.564
202203 3.149 121.301 3.421
202206 3.003 125.017 3.165
202209 2.899 125.227 3.051
202212 2.414 125.222 2.540
202303 1.642 127.348 1.699
202306 1.247 128.729 1.277
202309 0.909 129.860 0.922
202312 0.576 129.419 0.586
202403 0.329 131.776 0.329

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Organovo Holdings  (STU:4OR1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Organovo Holdings Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings (STU:4OR1) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

Organovo Holdings (STU:4OR1) Headlines

No Headlines